RHHBY Stock DD Roche Holding Ltd 08/11/2014 11:26:24

New Post Public Reply Private Reply Replies (0) Message Board

Aug 11, 2014 at 12:26 PM

RHHBY Roche Holding Ltd $RHHBY Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=RHHBY&am...mp;yt0=Go!

Last Updated: 08/11/2014 11:26:19

Current Price and Quotes
Last Price 35.87
Previous Close 35.92 Open 35.90
Daily Range 35.75 - 35.94 52wk Range 30.91 - 38.71
Volume 171,703 Dividend 0.70
Average Vol (30d) 572,299 Yield 1.9537

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 54,660,000 51,832,000 47,175,000 52,749,000
Cost of Revenue 13,435,000 13,301,000 12,771,000 14,261,000
Gross Profit 41,226,000 38,531,000 34,404,000 38,487,000
Operating Expenses

Research and Development 10,423,000 10,435,000 8,904,000 10,756,000
Sales, General and Admin. 12,389,000 12,664,000 11,112,000 13,263,000
Non-Recurring Items - - - -
Other - - - -
Operating Income 18,413,000 15,431,000 14,388,000 14,468,000
Income From Continuing Operations

Add'l Income/Expense Items (134,000) (47,000) 692,000 598,000
Earnings Before Interest and Tax 18,280,000 15,384,000 15,093,000 15,063,000
Interest Expense 1,777,000 2,101,000 2,383,000 3,035,000
Earnings Before Tax 16,503,000 13,283,000 12,710,000 12,028,000
Income Tax 3,715,000 2,730,000 2,503,000 2,489,000
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - 13,000 (3,000)
Net Income Cont. Operations 12,788,000 10,553,000 10,219,000 9,535,000
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 12,788,000 10,553,000 10,206,000 9,539,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 12,788,000 10,553,000 10,206,000 9,539,000

Recent News

Aug 8, 2014 Genentech Submits Supplemental Biologics License Application to FDA for Lucentis Indication in Diabetic Retinopathy
Aug 8, 2014 Small companies lead the I-O class of Cancer Therapies
Jul 29, 2014 Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo
Jul 24, 2014 The Zacks Analyst Blog Highlights: Biogen Idec, Roche Holding, AbbVie, AmSurg and Acadia Healthcare
Jul 22, 2014 FDA Grants Genentech's Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
Jul 15, 2014 FDA Grants Genentech's Avastin Priority Review for Certain Types of Cervical Cancer
Jul 14, 2014 Genentech's Investigational Medicine Cobimetinib, Used in Combination with Zelboraf(R) (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening
Jul 2, 2014 Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals
Jul 2, 2014 Seragon Pharmaceuticals Announces Acquisition Agreement With Genentech
Jun 10, 2014 Health Canada Approves Roche's HPV Test for First-Line Primary Screening of Cervical Cancer and Roche Launches New Cytology Test to Provide the Most Comprehensive Portfolio for Cervical Cancer Screening

1
2
next >

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

CVS Study: GLP-1 Drugs Effective But Costly

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...